Сurrent issues of maintaining patients with the operated valvular heart disease HTML

Authors: M.O. Lisina, I.A. Zhdanova, M.L. Ermolenko, M.N. Nevedrova, M.G. Meladze, D.A. Dzhandzhgava

Company: Bakoulev National Medical Research Center for Cardiovascular Surgery of Ministry of Health of the Russian Federation, Rublevskoe shosse, 135, Moscow, 121552, Russian Federation

Email: Log in or register.

Heading: Reviews

UDC: 616.126.3-007-089-08
DOI: https://doi.org/10.24022/1997-3187-2019-13-1-52-62

For citation: Lisina M.O., Zhdanova I.A., Ermolenko M.L., Nevedrova M.N., Meladze M.G., Dzhandzhgava D.A. Сurrent issues of maintaining patients with the operated valvular heart disease. Creative Cardiology. 2019; 13 (1): 52–62 (in Russ.). DOI: 10.24022/1997-3187-2019-13-1-52-62

Received / Accepted:  18.01.2019/25.01.2019

Key Words: prosthetic heart valves rehabilitation anticoagulant therapy

Abstract

Now hundreds of thousands of patients with the fitted a prosthesis heart valves live in the world. Application of everything types of artificial limbs is accompanied by a number of specific complications in the postoperative period, valvular implants peculiar to different groups. In this article questions of maintaining patients with the operated valvular heart disease are considered. The issues of follow-up of patients, prevention of bacterial endocarditis, recurrence of rheumatic fever, prevention of development and early detection of dysfunction of the prosthetic heart valve, identification of indications for valve re-prosthesis, physical and psychological rehabilitation of patients are considered in detail. Particular attention is paid to anticoagulant therapy in patients with biological and mechanical valve prostheses, as well as after valve plastic, perioperative management of patients receiving long-term anti-thrombotic therapy, and management of pregnancy.

References

  1. Pibarot P., Dumesnil J.G. Prosthetic heart valves: selection of the optimal prosthesis and long-term management. Circulation. 2009; 119 (7): 1034–48. DOI: 10.1161/CIRCULATIONAHA.108.778886.
  2. Butany J., Fayet C., Ahluwalia M.S., Blit P., Ahn C., Munroe C., Israel N. et al. Biological replacement heart valves. Identification and evaluation. Cardiovasc. Pathol. 2003; 12 (3): 119–39. DOI: 10.1016/S1054-8807(03)00002-4
  3. Baumgartner H., Falk V., Bax J.J., De Bonis M., Hamm C., Holm P.J. et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease: the Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2017; 38: 2739–91. DOI: 10.1093/eurheartj/ehx391
  4. Шостак Н.А., Бокерия Л.А., Гудкова Р.Г. Отечественная сердечно-сосудистая хирургия 2011. М.: НЦССХ им. А.М. Бакулева РАМН; 2012.
  5. Бокерия Л.A., Ступаков H.H., Гудкова Р.Г. Сердечно-сосудистая хирургия в России: методы оценки результатов и перспективы развития. Грудная и сердечно-сосудистая хирургия. 2002; 3: 4–11.
  6. Nishimura R.A., Otto C., Bonow R.O., Carabello B.A., Erwin J.P., Guyton R.A. et al. 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. 2014 AHA/ACC Valvular Heart Disease Guideline. Circulation. 2014; 129: 2440–92. DOI: 10.1161/CIR.0000000000000029
  7. Шостак Н.А., Клименко А.А., Андрияшкина Д.Ю., Кондрашов А.А., Новикова А.В. Роль антикоагулянтной терапии в лечении пациентов с протезированными клапанами сердца. Клиницист. 2016; 10 (2): 10–8. DOI: 10.17650/1818-8338-2016-10-2-10-17
  8. Шостак Н.А., Карпова Н.Ю., Рашид М.А., Пискунов Д.В. Аортальные пороки в практике ревматолога: аортальный стеноз. Consilium medicum. 2003; 11 (5): 620–3.
  9. Otto C.M., Prendergast B. Aortic-valve stenosis – from patients at risk to severe valve obstruction. N. Engl. J. Med. 2014; 371 (8): 744–56. DOI: 10.1056/NEJMra1313875
  10. Thourani V.H., Myung R., Kilgo P., Guyton R. Long-term outcomes after isolated aortic valve replacement in octogenarians: a modern perspective. Ann. Thorac. Surg. 2008; 86 (5): 1458–64. DOI: 10.1016/j.athoracsur.2008.06.036
  11. WilsonW., Taubert K.A., Gewitz M., Lockhart P.B., Baddour L.M., Levison M. et al. Prevention of infective endocarditis guidelines from the American Heart Association a guideline from the American Heart Association rheumatic fever, endocarditis, and Kawasaki Disease Committee, council on cardiovascular disease in the young, and the council on clinical cardiology, council on cardiovascular surgery and anesthesia, and the quality of care and outcomes research interdisciplinary working group. Circulation. 2007; 116: 1736–54. DOI: 10.1161/CIRCULATIONAHA.106.183095
  12. Salem D.N., O'Gara P.T., Madias C., Pauker S.G. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133 (6 Suppl.): 593S–629S. DOI: 10.1378/CHEST.08-0724
  13. Massel D.R., Little S.H. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst. Rev. 2013; 7: CD003464. DOI: 10.1002/14651858.CD003464.PUB2
  14. Regitz-Zagrosek V., Blomstrom L.C., Borghi C., Cifkova R., Ferreira R., Foidart J.-M. et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur. Heart J. 2011; 32 (24): 3147–97. DOI: 10.1093/eurheartj/ehr218
  15. Eikelboom J.W., Connolly S.J., Brueckmann M., Brueckmann M., Granger C.B., Kappetein A.P. et al. Dabigatran versus warfarin in patients with mechanical heart valves. N. Engl. J. Med. 2013; 369 (13): 1206–14. DOI: 10.1056/NEJMoa1300615
  16. Price J., Hynes M., Labinaz M., Ruel M., Boodhwani M. Mechanical valve thrombosis with dabigatran. J. Am. Coll. Cardiol. 2012; 60 (17): 1710–1. DOI: 10.1016/j.jacc.2012.06.039
  17. Stewart R.A., Astell H., Young L., White H.D. Thrombosis on a mechanical aortic valve whilst anti-coagulated with dabigatran. Heart Lung. Circ. 2012; 21 (1): 53–5. DOI: 10.1016/j.hlc.2011.08.014
  18. Van de Werf F., Brueckmann M., Connolly S.J., Friedman J., Granger C.B., Härtter S. et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatranetexilate in patients after heart valve replacement (RE-ALIGN). Am. Heart J. 2012; 163 (6): 931–7. DOI: 10.1016/j.ahj.2012.03.011
  19. Kaeberich A., Reindl I., Raaz U., Maegdefessel L., Vogt A., Linde T. et al. Comparison of unfractionated heparin, lowmolecularweight heparin, low-dose and highdose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study. J. Thromb. Thrombolysis. 2011; 32 (4): 417–25. DOI: 10.1007/s11239-011-0621-6
  20. Vitale N., De Feo M., De Santo L.S., Pollice A., Tedesco N., Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J. Am. Coll. Cardiol. 1999; 33 (6): 1637–41. DOI: 10.1016/S0735-1097(99)00044-3
  21. Massel D.R., Little S.H. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst. Rev. 2013; 7: CD003464. DOI: 10.1002/14651858.CD003464.pub2
  22. Pengo V., Palareti G., Cucchini U., Molinatti M., Del Bono R., Baudo F. et al. Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP). Clin. Appl. Thromb. Hemost. 2007; 13 (3): 241–8. DOI: 10.1159/000070420
  23. Søndergaard L., Saraste A., Christersson Ch., Vahanian A. The year in cardiology 2017: valvular heart disease. Eur. Heart J. 2018; 39 (8): 650–7. DOI: 10.1093/eurheartj/ehx772
  24. Реабилитация в кардиохирургии: https://medbe.ru/materials/kardiologicheskaya-reabilitatsiya/reabilitatsiya-v-kardiokhirurgii/ (дата обращения 12.01.2019).

About Authors

  • Marina O. Lisina, Researcher, orcid.org/0000-0002-8092-112X;
  • Inna A. Zhdanova, Junior Researcher, orcid.org/0000-0001-9948-716X;
  • Marina L. Ermolenko, Head of Department, orcid.org/0000-0002-7784-993X;
  • Mariya N. Nevedrova, Researcher, orcid.org/000-0002-5469-8999;
  • Mayya G. Meladze, Junior Researcher, orcid.org/0000-0002-3372-0456;
  • Daredzhan A. Dzhandzhgava, Researcher, orcid.org/0000-0003-2971-6873

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, Director of Bakoulev National Medical Research Center for Cardiovascular Surgery